PUBLISHED BY
Nagpal R, Butler K, Thal N, Hobill A, Gage A, Javed M, Karst F, Khan AA, Needleman A, Shirling G, Stephens H, Vivers S, Tavarozzi F, Mayor N, Frater S, Salama A, Harber M, Jones G, Fernando R and Evans
PUBLISHED IN
Transplant International
PATIENTS
1,348
ABSTRACT
HIGHLIGHTS
Strong outcomes with non-depleting induction
Kidney transplant recipients given Basiliximab achieved excellent 5-year survival (~87% patient, ~78% graft), showing non-depleting induction can be effective across many risk levels.
High sensitization still raises rejection risk
Highly sensitized recipients (cRF ≥ 85%) had lower graft survival and higher rejection rates, underscoring the need for more precise immunologic risk tools.
PIRCHE-T2 predicts rejection independently
Higher PIRCHE-T2 scores correlated with increased 12-month rejection (OR ≈ 1.6)and poorer graft survival, adding unique prognostic value beyond antibodysensitization.
cRF less predictive thanPIRCHE-T2
Calculated reaction frequency alone did not significantly predict rejection or graft survival, whereas PIRCHE-T2 did, suggesting its value in refining risk assessment.
Clinical takeaway
Non-depleting induction may be appropriate for many patients, but integratingPIRCHE-T2 scoring can better identify those who may benefit from stronger immunosuppression or closer monitoring.
